Previous 10 | Next 10 |
AtriCure press release ( NASDAQ: ATRC ): Q2 GAAP EPS of -$0.32 misses by $0.03 . Revenue of $84.53M (+18.4% Y/Y) beats by $4.86M . Full year 2022 revenue is projected to be approximately $323 million to $333 million, reflecting growth of approximately 18% to 21...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a ...
Cryoport has done well to grow its top line in recent years and some bottom line figures have also fared well. Growth is expected to continue this year, but this doesn't make the company a wise investment. Shares look very expensive right now and are unlikely to offer material ups...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2022 financial results on...
AtriCure presents with numerous inflection points that sit on the distant horizon. However, data from its operating performance suggests it has to overcome numerous idiosyncratic headwinds. The company has printed a series of operating, net and FCF losses in the years to date. ...
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effec...
AtriCure Inc. (ATRC) Q1 2022 Results Conference Call May 3, 2022 04:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants Robbie Marcus - JPMorgan Danielle Antalffy - SVB Leerink John McAulay - Stifel Sam ...
AtriCure press release (NASDAQ:ATRC): Q1 Non-GAAP EPS of -$0.33 beats by $0.01. Revenue of $74.58M beats by $3.41M. For FY22 revenue is projected to be ~$318M-330M, Non-GAAP EPS of ~$1.07-1.12 For further details see: AtriCure Non-GAAP EPS of -$0.33 beats by $0.01, revenue of $74.58M be...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results. “Our team deliver...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...